Atopic Dermatitis is a big market. Regeneron's $REGN Dupixent leads in sales ($1b/yr annualized) but $DERM wants some of that action. The firm reported positive clinical results for its IL-13 study.The stock is up 70%+: $DERM, Dermira, Inc. / H1 Our membership-only pick $XBIT is another top idea. Members bought the stock well in the $2 - $5 range: $XBIT, XBiotech Inc. / H1 $REGN PT $40 established last year met. We have a hold. $REGN, Regeneron Pharmaceuticals, Inc. / H1 REGN stock traded 10% the PT at $442 at the start of this month.In the oncology space, $LPTX will Present at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer. Ahead of the news, the stock is trading to price in the information shared: $LPTX, Leap Therapeutics, Inc. / H1